Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly

L A Thomas, M J Veysey, G M Murphy, D Russell-Jones, G L French, J A H Wass, R H Dowling

Background: Acromegalic patients have slow colonic transit, increased rates of deoxycholic acid formation, and an increased prevalence of cholesterol gall stones, especially during long term octreotide treatment. However, the effects of this prolonged large bowel transit time on the numbers of faecal anaerobes and the activities of the enzyme systems which biotransform conjugated cholic acid into unconjugated deoxycholic acid (cholehydrolase and 7α-dehydroxylation) are unknown.

Methods: Therefore, in 10 non-acromegalic controls, 11 acromegalics not treated with octreotide, and 11 acromegalics on long term (8–48 months) octreotide (100–200 μg three times daily subcutaneously), we measured large bowel transit time and, in freshly voided faeces, the activities of the two bile acid metabolising enzymes, and related the results to the proportion of deoxycholic acid in fasting serum. Moreover, in patients with acromegaly, we measured quantitative bacteriology in faeces.

Results: Mean large bowel transit time in acromegalics not treated with octreotide (35 (SEM 6.5) hours) was 66% longer than that in non-acromegalic controls (21 (3.1) hours; NS) and became further prolonged during octreotide treatment (48 (6.6) hours; p<0.001). These octreotide induced changes in transit were associated, in acromegalics, with more total (15.0 (2.5) v 6.3 (1.3)×10⁶ colony forming units (cfu)/g, p<0.05) and Gram positive (6.3 (2.3) v 3.2 (1.0)×10⁶ cfu/g, p<0.05) faecal anaerobes. Mean faecal cholehydrolase activity in the long term octreotide group (22.0 (6.0)×10⁻³ U/mg protein) was 138% greater than that in non-acromegalic controls (12.0 (6.0)×10⁻³; p<0.01). Similarly, mean 7α-dehydroxylase activity in octreotide treated acromegalics (11.1 (1.8)×10⁻⁴ U/mg protein) was 78% greater than that in patients not receiving long term octreotide (6.3 (0.5)×10⁻⁴; p<0.001). The mean proportion of deoxycholic acid in fasting serum also increased from 18.0 (2.88)% in the untreated group to 29.6 (2.5)% during long term octreotide (p<0.05). There were significant linear relationships between large bowel transit time and: (i) faecal 7α-dehydroxylase activity; and (ii) the proportion of deoxycholic acid in fasting serum and between 7α-dehydroxylase activity and the proportion of deoxycholic acid in serum.

Summary/interpretation: These data suggest that increased deoxycholic acid formation seen in acromegalic patients during octreotide treatment is due not only to the greater numbers of faecal anaerobes but also to increased activity of the rate limiting enzyme pathway (7α-dehydroxylation) converting cholic acid to deoxycholic acid.

Octreotide (OT) is a long acting analogue of somatostatin. It suppresses both growth hormone (GH) and insulin-like growth factor 1 (IGF-1) and is therefore an effective treatment for acromegaly. However, after one to two years of OT therapy, 10–60% (mean 29%) of acromegalic patients develop cholesterol rich gall bladder stones (GBS). OT treatment impairs gall bladder emptying.6 7 However, this is not the sole mechanism for OT induced GBS formation: these iatrogenic stones may also develop as a result of prolonged intestinal transit.8 9 We showed previously that patients with OT induced GBS not only have prolonged large bowel transit but they also have changes in bile composition and physical chemistry similar to those seen in “conventional” gall stone disease (unrelated to acromegaly or OT treatment).8 Thus OT treated acromegalic patients have supersaturated bile, excess biliary cholesterol in vesicles, a high biliary vesicular cholesterol:phospholipid molar ratio, and abnormally rapid nucleation of cholesterol microcrystals. These changes are associated with a doubling in the mean percent of deoxycholic acid (DCA) conjugates in gall bladder bile. Moreover the results of paired, before, and during OT treatment studies suggest that this increase in per cent DCA in bile is due to OT treatment, independent of iatrogenic stone formation.9 10 Although we proposed that the mechanism for this increase in biliary DCA is prolongation of colonic transit,7 8 9 we did not know how changes in large bowel transit time (LBTT) might increase the per cent DCA in serum and bile.

We previously studied spontaneous gall stone disease in non-acromegalic patients.11 In these studies, we found that gall stone carriers had increased numbers of both total anaerobes and Gram positive anaerobic bacteria capable of bile acid deconjugation (cholehydrolase)9 10 and 7α-dehydroxylation (7α-dehydroxylase).11 However, these data were measured in fresh caecal aspirates obtained during colonoscopy rather than in faeces. The gall stone carriers also had increased bile acid metabolising enzyme activities compared with stone free controls. It seemed important therefore to see whether...

Abbreviations: cfu, colony forming units; CGH, cholehydrolase; DCA, deoxycholic acid; GBS, gall bladder stones; GH, growth hormone; IGF-1, insulin-like growth factor 1; LBTT, large bowel transit time; OT, octreotide; 7α-DH, 7α-dehydroxylase; TLC, thin layer chromatography
comparable changes in bacteriology and bile acid metabolising enzymes also occurred in acromegalic patients.

The aims of this study were to compare colonic transit, bile acid metabolising enzyme activities, and the per cent DCA (%DCA) in fasting serum in control subjects and in two groups of acromegalic patients—those not treated with OT and those receiving long term OT treatment—and to compare quantitative faecal bacteriology in the two groups of patients with acromegaly. Then, using univariate analyses, we examined the interrelationships between: (i) LBTT; (ii) qualitative and quantitative changes in fresh faecal microflora; (iii) faecal bacterial deconjugating and 7α-dehydroxylation enzyme activities; and (iv) %DCA in fasting serum (and by implication in bile).

**STUDY DESIGN, PATIENTS, AND METHODS**

**Study design**

With few exceptions, the design of this study was similar to that of our companion paper. Thus we again measured LBTT, quantitative bacteriology, the associated bile acid metabolising enzyme activities, and %DCA in fasting serum. However, we did so in acromegalic patients not treated with OT and in those receiving long term OT therapy (none of whom had GBS) and compared the results with those in a historic group of non-acromegalic stone free controls (see below). Moreover, in the present study, we measured faecal, rather than proximal colonic, samples while in non-acromegalic control subjects there was no quantitative bacteriology.

Furthermore, because the acromegalic patients lived in distant parts of the country and were unable to return to Guy’s Hospital each day for retrieval of pH-telemetry data, we did not measure colonic luminal pH.

**Patients**

Three groups of individuals were studied:

**Non-acromegalic ‘controls’** (n = 10)

These patients were aged 48 (SEM 2.4) years (range 26–65) and six of them were women. All had undergone clinically indicated colonoscopy (because of fresh rectal bleeding in four, cancer surveillance in five, and symptoms of the irritable bowel syndrome in one) but were found, in retrospect, to have normal colons by endoscopy and on histology of mucosal biopsies. The 10 patients in this group were common to 10 of the 20 “control subjects” in our companion paper. For this reason, the results for two of the six variables (LBTT and %DCA in fasting serum) have been presented previously. However, we were able to obtain faecal samples from only 10 of these 20 historic controls: this was the sole basis for selecting this subset of individuals for comparison with acromegalic patients.

**Acromegalic patients not treated with OT (n = 11)**

These individuals were aged 46 (3.5) years (range 30–68) and five were women.

**Acromegalic patients treated long term with OT (n = 11)**

These patients were aged 46 (2.9) years (range 31–70) and seven were women. They were treated for 8–48 months (median 22 months) with 100–200 μg OT three times daily by subcutaneous injection.

In the 22 acromegalic patients, the diagnosis of acromegaly was based on the following criteria: failure of suppression of serum GH levels to less than 2 mU/l after an oral glucose (75 g) load; a mean daily serum GH level of more than 5 mU/l (averaged from five samples taken over a 12 hour period), and increased age adjusted IGF-1 levels in serum.

All 32 individuals studied were gall stone free, as judged by ultrasound scanning of the biliary tree not more than one month before entering the study. All 32 were encouraged to maintain their normal diets and patterns of defecation during the investigations: none had taken antibiotics, laxatives, or other drugs known to affect intestinal transit or the colonic bacterial flora for one month before the study.

**Methods**

**Large bowel transit time (LBTT)**

Colonic transit was measured by the Metcalf technique. In brief, patients swallowed capsules containing radio-opaque markers on days 1, 2, and 3 of the study and then had a plain abdominal x ray on day 4 to count the number of residual markers, and from this, LBTT was calculated using a simple formula.

**Collection of fresh faecal samples**

Patients delivered a faecal sample to the Gastroenterology Unit within four hours of defecation. These samples were stored in sealed plastic containers and transferred to the Microbiology Department in an anaerobic transport bag within one hour of receipt. A 1 g aliquot of each faecal sample was homogenised with 10 ml of sterile saline (rendered anaerobic with nitrogen gas). The homogenate was also maintained in an anaerobic environment during transfer to the collection point in the Microbiology Department.

**Quantitative bacteriology**

The microbiological techniques used in this study were based on those of Summanen and colleagues, as described previously. For all the patients studied, the time interval between measurement of LBTT and bile acid metabolising enzymes never exceeded 28 days.

**Bile acid metabolising enzyme activities**

A 10 ml aliquot of each homogenised faecal sample was first sonicated in an ice bath. Proteins in the sonicates were then precipitated using saturated ammonium sulphate, and their concentrations measured using the Lowry method. Bile acid metabolising enzyme activities were assayed, and the results expressed as units of enzyme activity per mg of faecal protein, where 1 unit = 1 μmol of product formed per mg of bacterial protein per minute.

**(i) Deconjugation: cholyglycine hydrolase (CGH)**

The substrate for the deconjugation reaction was 10 mM taurocholic acid, and 0.5 ml of the protein extract from the faecal homogenates were incubated with 0.5 ml of this substrate, as previously described. The product of this reaction (unconjugated cholic acid) was extracted using a C18 column, isolated by thin layer chromatography (TLC), and measured with the 3α-hydroxysteroid dehydrogenase enzyme assay at 340 nm.

**(ii) Dehydroxylation: the cholic acid 7α-dehydroxylase (7α-DH) system**

The reaction conditions for this enzyme pathway were also as previously described. In brief, 0.5 ml of the protein extract were incubated with 200 μl of 2 mM non-isotopic cholic acid which was used to catalyse the reaction by substrate-enzyme induction, plus 200 000 dpm of 14C-cholic acid. Bile acids in the reaction mixture were extracted twice using ethyl acetate, separated, and the product (unconjugated DCA) identified using TLC. The 14C radioactivity in this DCA fraction was then measured in a liquid scintillation counter (LKB 81,000; Sweden), using both internal and external quench correction.
Measurement of %DCA in fasting serum
Concentrations of individual bile acids were measured in fasting serum using gas chromatography-mass spectrometry, as previously described. The relative proportions of total DCA in serum were then calculated and expressed as percentages of total serum bile acids, respectively.

Statistical analyses
Unless otherwise stated, results are expressed as means (SEM). The significance of differences in results between the groups was tested using the t test, using Excel software version 5.0 (Microsoft Corporation, Redmond, Washington, USA). A p value of <0.05 was considered to be statistically significant.

We used univariate analyses to examine the relationships between: (i) LBTT; (ii) qualitative and quantitative changes in the fresh faecal microflora; (iii) faecal bacterial deconjugating and \( \text{7}\alpha \text{-dehydroxylation enzyme activities; and (iv)} \%DCA \) in fasting serum.

Ethical considerations
The study was approved by the Research Ethics Committee of Guys and St Thomas’ Hospitals. All 32 patients gave written informed consent.

RESULTS
Large bowel transit time (LBTT)
The results for LBTT in the three groups of individuals are shown in fig 1.

There was a considerable scatter of results with some overlap for data between the three groups and although the mean value in acromegalic patients not treated with OT (35 (6.5) hours) was 66% greater than that in non-acromegalic controls (21 (3.1) hours), this difference was not statistically significant. However, in OT treated acromegalics, the mean value of 48 (6.6) hours was 129% greater than that in controls (p<0.001) and 37% greater than that in untreated acromegalics (p<0.05).

Faecal total and Gram positive anaerobic bacterial counts
The mean total anaerobic count in acromegalic patients treated long term with octreotide \( (15.0 \times 10^9 \text{ cfu/g faeces}) \) was 138% greater than that in acromegalic patients not treated with OT \( (6.3 \times 10^9 \text{ cfu/g faeces}) \); p<0.05). There was a similar pattern of results for Gram positive anaerobes; the mean count in OT treated patients \( (6.3 \times 10^9 \text{ cfu/g faeces}) \) was 97% greater than that in acromegalic patients who had not been treated with the somatostatin analogue \( (3.2 \times 10^9 \text{ cfu/g faeces}) \); p<0.05).

Bile acid metabolising enzyme activities
Deconjugation: cholyglycine hydrolase
The results for CGH activity in all three groups of patients are shown in fig 2.

The overall pattern of results for CGH was broadly similar to that described above for LBTT. Despite a 75% increase in mean activity, there was no significant difference between controls \( (12.0 \times 10^{-2} \text{ U/mg protein}) \) and acromegalics not treated with OT \( (21.0 \times 10^{-2} \text{ U/mg protein}) \), and no significant difference between the two groups of acromegalic patients. However, mean CGH in acromegalic patients on long term OT \( (22.0 \times 10^{-2} \text{ U/mg protein}) \) was significantly greater than that in non-acromegalic controls (p<0.01).

\( \text{7}\alpha\text{-dehydroxylation: cholic acid 7}\alpha\text{-dehydroxylase (7}\alpha\text{-DH)} \)

Data for \( \text{7}\alpha\text{-DH} \) specific activities are illustrated in fig 3.

The pattern of results for the dehydroxylating enzyme system was also similar to those for LBTT and the deconjugating enzyme (CGH). Again, the highest specific activities were seen in acromegalic patients on long term octreotide treatment in whom the mean value of 11.13 \( (1.18 \times 10^{-4} \text{ U/mg protein}) \) was 78% greater than that in
acromegalic patients on long term octreotide treatment (Acrom LTOT).

**Fasting serum deoxycholic acid**

The results for fasting serum total DCA, expressed as a percentage of serum total bile acids, are shown in fig 4.

As with other variables, there was no significant difference in the mean proportions of DCA between non-acromegalic controls (14.9 (1.85)%) and patients with acromegaly who had not been treated with the somatostatin analogue (18.0 (2.88)%). However, in acromegalic patients treated chronically with OT, the mean proportion of DCA (29.6 (2.3)%) was significantly greater than that in acromegalic controls who had not been treated with OT (p<0.05), and than that in controls (p<0.001).

**Relationship between LBTT and the faecal 7α-DH enzyme pathway**

The relationship between LBTT and the activity of the 7α-DH enzyme system is plotted graphically in fig 5.

As indicated in fig 5, there was a weak (r = 0.57) but significant (p<0.001) positive linear relationship between these two variables—that is, the longer the colonic transit time, the greater was the specific activity of the rate limiting enzyme pathway in DCA formation.

**Relationship between LBTT and %DCA in fasting serum**

The plot of serum DCA (% of total bile acids) versus faecal 7α-DH activity is shown in fig 6.

The correlation coefficient for these two variables (r = 0.63) was slightly higher than that noted in fig 5, and again this linear relationship was statistically significant (p<0.001).

**DISCUSSION**

This study forms part of an ongoing programme of research in our unit into the pathogenesis of cholesterol rich GBS with particular emphasis on the role of DCA in the development of OT induced, and spontaneously occurring, GBS. The results of the present study, when combined with those of our companion paper, suggest that prolongation of colonic transit leads to increased numbers of total and Gram positive anaerobic bacteria, and increased activities of the bile acid deconjugating and 7α-dehydroxylating enzymes, within the colon. In turn, this combination of events leads to increased proportions of DCA in serum and, by implication, in bile—a putative, although controversial, risk factor for cholesterol gall stone formation.

Why prolongation of large bowel transit should increase the numbers of anaerobic bacteria in the colon and faeces is not clear but there are several possible explanations. Firstly, the increased residence time of luminal contents within the colon could allow more time for bacterial proliferation. Secondly, transit related changes in colonic luminal pH may be important. Prolongation of LBTT is known to increase colonic luminal pH and in vitro (that is, in a “Chemostat” system), increases in pH encourage the growth of anaerobic bacteria, including Gram positive anaerobes. Thirdly,
although we have argued that it is the slowing of large bowel transit which is responsible for the greater numbers of colonic bacteria in acromegalic patients (particularly those treated long term with OT), in theory it could be DCA itself—rather than the prolonged transit—which influences bacterial growth.

**Study design, patients, and methods**

**Patient selection**

Although the main emphasis in this report was on acromegalic patients (studied before and during octreotide therapy), we felt it important to also include a control group of non-acromegalic stone free individuals. We did so because of the unresolved controversy about whether acromegaly itself (independent of OT treatment) is a risk factor for cholesterol stones. For this reason, we recruited the subset of 10 stone free individuals from a total of 20 controls in our companion study. In part, therefore, these 10 were historic controls and some of their results have been presented previously. However, they were selected solely on the basis of their ability and willingness to provide faecal samples. We believe that this selection criterion did not bias the results: certainly mean LBTTs and mean proportions of DCA in fasting serum in this subgroup of patients were not significantly different from those in the original 20 stone free controls.

**Faecal vs caecal sampling for quantitative bacteriology and measurement of bile acid metabolising enzyme activities**

In our companion report, we studied quantitative bacteriology and bile acid metabolising enzyme activities in caecal aspirates, rather than in freshly voided faeces. Indeed, there were compelling theoretical reasons for doing so. The numbers of anaerobes are different at the two sites—bile acid deconjugation and 7α-dehydroxylation take place mainly in the caecum and ascending colon, rather than in the left side of the colon. That being the case, why did we opt to sample faeces in the present study? We did so for three reasons. Firstly, the present study was carried out mainly in acromegalic patients in whom colonoscopy is technically difficult, in part because they have long colons. Secondly, acromegalic patients have a high prevalence and incidence of large bowel polyps and cancers, many of which are found on the right side of the colon. For this reason many centres, including our own, recommend that acromegalic patients should undergo endoscopy of the whole colon (and not just left sided flexible sigmoidoscopy) to exclude polyps and cancers. This involves full bowel preparation with oral purgation. Had we adopted such an approach in the present study, it would inevitably have disturbed the normal bacterial flora, and probably also the bile acid metabolising enzyme activities in the caecum. For ethical reasons, we did not feel justified in proposing two colonoscopic examinations in these patients: (i) a clinically indicated full colonoscopy (after oral purgation) to exclude polyps and cancers, and (ii) a limited examination of the left side of the colon (instant enema only with no oral purgation) plus caecal sampling for clinical research purposes.

Thirdly, in a separate, but related, study we compared bacterial bile acid metabolising enzyme activities in caecal and faecal samples, obtained at the same time from the same individuals. Although CGH activities were comparable at both sites, the mean activity of 7α-DH in faeces was significantly lower than that in aspirates from the proximal colon. However, the magnitude of the difference in 7α-DH activity between the caecal and faecal samples was small. Moreover, 7α-DH activity at one site predicted that at the other.

**Comparison of results in non-acromegalic controls and acromegalic patients not treated with octreotide**

As the present results show, for three of the four variables measured (LBTT, CGH activity, and %DCA in serum), mean values in acromegalic patients not treated with OT were 23–75% higher than those in non-acromegalic controls. However, none of these differences was statistically significant: in part because of the scatter of results and in part because of the relatively small numbers in the two groups studied. The fact remains that in a previous study we found that mean LBTT and %DCA in fasting serum were significantly greater in acromegalic patients who had not received OT than in non-acromegalic controls. Moreover, when the data from five separate studies (in which the same protocol was used) were pooled, untreated acromegals showed obvious and significant increases in both parameters compared with non-acromegalic controls.

The implication of these observations is that one might expect an increased prevalence of cholesterol gall bladder stones in acromegaly. The evidence on this point is inconclusive because the number of studies addressing this problem is limited, the numbers of individuals surveyed in these studies were small, and comparisons in them were not based on case control studies but rather on values for gall stone prevalence from previously published epidemiological studies. In fact, Catnach and colleagues found a significant increase in the prevalence of gall stones in British acromegalic patients compared with that in age and sex matched controls from Bristol.

The relevance of the present observations to spontaneous gall stone disease, and indeed to OT induced gall stones in acromegaly, depends on the validity of several assumptions: (i) that %DCA in serum is a valid surrogate marker for the proportion of this hydrophobic bile acid in bile, (ii) %DCA in bile influences biliary cholesterol secretion and saturation, and (iii) that supersaturated gall bladder bile itself predicts the risk of cholesterol gall stone formation. We believe that these assumptions are probably valid although the evidence to support them is reasonable rather than strong. This evidence has been reviewed fully elsewhere and need not be repeated here.

Even if there is an increased incidence and/or prevalence of gall stones in acromegalic patients not treated with somatostatin analogues, the fact remains that the pathogenesis of all cholesterol rich GBS is multifactorial. Therefore, even if present, the roles of prolonged colonic transit and of increased DCA formation/absorption in the genesis of gall stones in acromegaly may be modest.

**ACKNOWLEDGEMENTS**

We are grateful to Professor Phil Hylemon, Virginia Commonwealth University, Richmond, Virginia, USA, for his valued assistance in establishing our enzyme assay techniques, and to Dr Nigel Smeeton, GKT School of Medicine, for his help with statistics and study design.

**Authors’ affiliations**

L A Thomas, M J Veysey, G M Murphy, R H Dowling, Gastroenterology Unit, Division of Medicine, Guy's Hospital Campus, GKT School of Medicine, Kings College, London, UK

D Russell-Jones, Department of Endocrinology, St Thomas Campus, GKT School of Medicine, Kings College, London, UK

G L French, Department of Microbiology, St Thomas Campus, GKT School of Medicine, Kings College, London, UK

J A H Wass, Department of Endocrinology, Radcliffe Infirmary, Oxford, UK

Conflict of interest: None declared.

This work was presented in part at the Meeting of the American Gastroenterological Association (Gastroenterology 1998;114:A546).

---

www.gutjnl.com
REFERENCES


www.gutjnl.com
Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly

L A Thomas, M J Veysey, G M Murphy, D Russell-Jones, G L French, J A H Wass and R H Dowling

Gut 2005 54: 630-635
doi: 10.1136/gut.2003.028431

Updated information and services can be found at:
http://gut.bmj.com/content/54/5/630

These include:

References
This article cites 41 articles, 13 of which you can access for free at:
http://gut.bmj.com/content/54/5/630#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/